The invention provides computer-implemented method and system for mediating a robot-centric data schema to a building-centric data schema for representing a robot is provided. The building-centric data schema represents the robot with a plurality links representing non-deformable parts of the robot and a plurality of joints describing relationship between the links. The method comprises: extracting robot information from the robot-centric data schema; creating a robot container to model the robot as a whole-part structure; translating the plurality of links and the plurality of joints from the robot-centric data schema to the building-centric data schema based on the extracted robot information; filling the robot container with the translated links and translated joints; and constructing the building-centric data schema with the robot container filled with the translated links and translated joints.
A moving object detection system and method is provided. The system includes an input module capturing a point cloud comprising measurements of distances to points on one or more objects and a detection module receiving the point cloud captured by the input module and configured to determine whether the objects are moving objects. The determination of moving objects is performed by determining whether currently measured points occlude any previously measured points, and/or whether the currently measured points recursively occlude any previously measured points, and/or whether the currently measured points are recursively occluded by any previously measured points.
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (Chine)
Inventeur(s)
Chen, Zhiwei
Luo, Mengxiao
Zhou, Runhong
Abrégé
Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A hoisting posture control system and method, applicable to the technical field of modular construction. According to the hoisting posture control system, controllers corresponding to functional modules are called on the basis of data detected by sensors, to drive posture control of a hoisted object, thereby assisting a tower crane operator in making work decisions, so that the operator does not need to take risks to get close to a module to be installed hoisted in the air, ensuring the safety of workers and the accuracy and reliability of module installation. Thus, the labor cost in modular construction work can be reduced, and the assembly quality and efficiency of modules are improved.
B66C 13/08 - Dispositifs auxiliaires pour commander les mouvements des charges suspendues ou pour empêcher le câble de prendre du mou pour déposer les charges selon un orientement ou dans une position donnés
B66C 13/06 - Dispositifs auxiliaires pour commander les mouvements des charges suspendues ou pour empêcher le câble de prendre du mou pour limiter ou empêcher le balancement longitudinal ou transversal des charges
B66C 13/48 - Commande automatique de l'entraînement des grues pour produire un cycle de travail unique ou répétéCommande par programmation
B66C 13/16 - Utilisation de dispositifs indicateurs de positionnement ou de pesée
B66C 1/12 - Élingues comportant chaînes, fils métalliques, cordes ou bandesFilets
5.
HOISTING POSITION AND POSTURE ADJUSTMENT SYSTEM AND HOISTING APPARATUS
A hoisting position and posture adjustment system and a hoisting apparatus. The hoisting apparatus comprises the hoisting position and posture adjustment system, wherein the hoisting position and posture adjustment system comprises a posture adjustment device (20), a hoisting frame (11), a horizontal-displacement adjustment device (13) and a lifting spreader (12) which are sequentially arranged in a vertical direction, the lifting spreader (12) being connected to the hoisting frame (11) or the horizontal-displacement adjustment device (13) and configured to connect to a hoisted object (300); the horizontal-displacement adjustment device (13) is connected to the hoisting frame (11) and is configured to adjust the horizontal position of the hoisted object (300); and the posture adjustment device (20) is connected to the hoisting frame (11) and is configured to adjust the posture of the hoisted object (300), so as to keep the hoisted object (300) in a horizontal posture. By means of the cooperation of the horizontal-displacement adjustment device and the posture adjustment device, the hoisting position and posture adjustment system of the present application can automatically fine-tune the position and posture of a hoisted object, such that the amount of manual participation can be significantly reduced, thereby facilitating a reduction in labor costs and safety risks; moreover, the hoisted object can be accurately placed at a target position, thereby reducing the dependence on workers.
B66C 13/08 - Dispositifs auxiliaires pour commander les mouvements des charges suspendues ou pour empêcher le câble de prendre du mou pour déposer les charges selon un orientement ou dans une position donnés
B66C 1/12 - Élingues comportant chaînes, fils métalliques, cordes ou bandesFilets
6.
COMPOSITIONS AND METHODS FOR THE FABRICATION OF SUPRAMOLECULAR MATERIALS WITH NANOSTRUCTURES AND SPATIALLY DISTINCT FEATURES
Supramolecular nanostructures having spatially distinct features and methods for the preparation of such nanostructures are disclosed. The supramolecular nanostructures are composed of planar, or linear small molecules associated with each other through non-covalent interactions including, but not limited to, metal-metal interactions, π-π interactions, hydrogen bonding interactions, solvophobic-solvophobic interactions, or a combination thereof, and polymer components stabilized by non-covalent interactions. These supramolecular nanostructure materials can exhibit a wide variety of functional properties due to the two chemically diverse components, in which a great flexibility and a large variety of choices are available, enabling options to control the supramolecular nanostructure's luminescence properties and compositions.
A stretchable, conducting, and redox-active hydrogel with an interpenetrating double-network structure is provided. This structure is formed by infiltrating a brittle pure-gel conducting hydrogel with a stretchable hydrogel. Ferrocene derivatives are immobilized on the chains of the stretchable hydrogel through covalent bonds, and glucose oxidases are crosslinked to the stretchable hydrogel using a room-temperature crosslinker.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1477 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques non invasifs
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
8.
FLEXIBLE MICRO-NEEDLE ELECTRODE FOR BIOPOTENTIAL MONITORING, A METHOD FOR CONSTRUCTING THE FLEXIBLE MICRO-NEEDLE ELECTRODE AND A PATCH ELECTRODE COMPRISING THE FLEXIBLE MICRO-NEEDLE ELECTRODE
A flexible micro-needle electrode for biopotential monitoring, a method for constructing the flexible micro-needle electrode and a patch electrode comprising the flexible micro-needle electrode. The method comprises the steps of providing a negative stamp that has been structured with a plurality of micro-needle structures; depositing at least one layer of electrically conductive material onto the negative stamp; and peeling off the at least one layer of electrically conductive material from the negative stamp to obtain the flexible micro-needle electrode comprising the at least one layer of electrically conductive material defined with the plurality of micro-needle structures.
A hot stamping method for pre-coated steel plate comprises performing a preliminary heat treatment on the pre-coated steel plate before hot stamping. The preliminary heat treatment comprising: (1) a step of heating and temperature holding involving: heating the pre-coated steel plate to 850-920° C. and holding the temperature for 7 to 15 minutes, or heating to 920-960° C. and holding the temperature for 5 to 10 minutes; (2) cooling the pre-coated steel plate to below 300° C. after the step of heating and temperature holding at a cooling rate not less than 5° C./s; and (3) optionally repeating the step of heating and temperature holding and the step of cooling one or more times. The preliminary heat treatment increases the alloying degree of the pre-coating layer, reduces the carbide structures in the steel plate matrix, and obtains a martensite and/or bainite matrix structure, so as to reduce damage to a stamping die.
A devices and systems for removing dental plaque/oral biofilms from a target surface or all surfaces of a tooth contains a socket head, a socket ball, and a pair of opposing bilateral wings. The socket ball is mounted in a joint-housing of the socket head, forming a ball-and-socket joint. The bilateral wings are connected to the socket head and extend downwardly. Each wing may include one or more cleaning elements, such as water cannons, water cannon folds, mega-/micro-nipples, and/or mega-/micro-nipple coupled water cannons. A system containing the device typically includes one or more additional components configured to incorporate the device into an element for user operation and link the device to a flow path, providing a fluid/air flow path for supplying a liquid and/or air to the device.
Disclosed are methods and materials for treating a subject having hepatocellular carcinoma (HCC). The methods and materials are useful, for example, for conversion of locally advanced, unresectable HCC. For example, the disclosed methods and materials are useful for conversion of locally advanced, unresectable HCC. The methods generally include sequential combination of three treatments: transarterial chemoembolization (TACE); stereotactic body radiotherapy (SBRT); and immunotherapy with an immune checkpoint inhibitor.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
12.
SYNERGISTIC CONTROL AND DYNAMIC ASSEMBLY OF VISCOELASTIC NETWORKS AND BIOMOLECULAR CONDENSATES BY AQUEOUS LIQUID-LIQUID PHASE SEPARATION AND LIQUID-SOLID PHASE SEPARATION (AQLL-LS PS2)
A biological network mimic for investigating subcellular structures and their interaction with biomolecular condensates is presented. The mimic is a stimulus-responsive polymer and a non-responsive polymer in an aqueous two-phase system (ATPS). One effective mimic is an aqueous two-phase system (ATPS) that combines poly (N-isopropylacrylamide) (PNIPAM) and dextran (DEX). The ATPS mimic, displays ultrasensitive thermo-induced aqueous liquid-liquid phase separation and liquid-solid phase separation (AqLL-LS PS2). Diverse structures, including networks, hollow spheres, and spinodal decomposition-like patterns, are generated by regulating component concentrations and temperatures. These structures are thermally reconfigurable. Networks can melt fused in sarcoma (FUS) condensates. The mimics provides methods to examine potential treatments of neurode-generative diseases by dissolving pathologically relevant biomolecular condensates.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Described herein are heterogeneous catalysts and methods of making and using thereof. For instance, heterogeneous catalysts formed of bisphosphine-ligated copper(I) complexes on a metal-organic framework support can be used, for example, in cycloaddition reactions.
Zhongshan Ophthalmic Center, Sun Yat-sen University (Chine)
Inventeur(s)
Wang, Weiping
Liang, Xiaoling
Zhou, Yang
Li, Jia
Abrégé
Provided herein is a photoresponsive prodrug comprising an active agent conjugated to a photoresponsive group, and a nanoparticle, wherein the photoresponsive prodrug is co-assembled with a polymer to form a nanoparticle. Also provided is a method of treating a subject, comprising administering photoresponsive prodrug or the nanoparticle to the subject, and irradiating at the target site with a light source.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
15.
SYSTEM AND METHODS FOR QUANTIFYING AND CALCULATING WINDOW VIEW OPENNESS INDEXES
A method and systems for quantifying and calculating window view openness indexes based on window view photos and view distances are provided. The method includes generating a window view image by an image capturing device; computing a distant view layer proportion; measuring and computing a close-range view layer distance; computing a view distance-based openness adjustment factor (OAF); and computing a window view openness index (WVOI). The computing of a distant view layer proportion may include extracting a proportion of a distant layer of the window view image as a basic factor to measure view openness. The OAF is summarized from view distances computed in the step of measuring and computing a close-range view layer distance. The WVOI is calculated based on the proportion of distant view layer and the OAF from the close-range view layer distance.
Provided in the present invention are an anode for a PEM water electrolytic cell and a preparation method for the anode. The anode comprises a stainless steel base body and a layered oxide structure generated on the surface of the stainless steel base body in situ, wherein the layered oxide structure comprises a manganese-deficient inner layer and a manganese-rich outer layer, the manganese-rich outer layer comprising a crystal manganese oxide secondary outer layer and an amorphous iron-containing manganese oxide outermost layer. The layered oxide structure of the surface of the anode of the present invention can maintain long-time catalytic activity for electrolysis of water and stability under acidic conditions, and an appropriate surface structural component selection solves the problems of corrosion and stability of self-catalysis and non-noble metal electrodes in an acidic environment. The anode provided in the present invention significantly reduces the present cost of hydrogen production based on a noble metal catalyst, and is expected to solve high-cost problem of PEM large-scale electrolysis hydrogen production.
C25B 11/053 - Électrodes comportant un substrat et un ou plusieurs revêtements électro-catalytiques caractérisées par des revêtements électro-catalytiques multicouches
C25B 11/052 - Électrodes comportant un substrat et un ou plusieurs revêtements électro-catalytiques
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
A method of fabricating a crack-free anionic network polymer (ANP) electrolyte membrane by conjugating anionic nodes (Monomer-Cl) with a short alkene possessing a C═C (carbon double bond) terminal group to form a structure with alkene moieties, mixing the modified anionic nodes with an ionic conductive polymer linker in organic solvent and exposing the mixture to ultraviolet (UV) light to triggers a polymerization process via click reaction to form a crack-free anionic network polymer carbon double bond (ANP-C) membrane. Forming a lithium battery from the membrane when the anionic nodes are lithium tetrakis 4-(chloromethyl)-2.3.5.6-tetrafluorophenyl) borate and the short alkene is 5-hexenol.
H01M 10/0565 - Matériaux polymères, p. ex. du type gel ou du type solide
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
18.
PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATING HIV-1 INFECTION
Pharmaceutical composition for treatment of HIV-1 infection comprising nicotinamide mononucleotide (NMN) as active ingredient. And use of NMN for preparation of medicament.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
Compositions, kits and methods of determining the presence of nasopharyngeal carcinoma (NPC) in a subject or relapse prediction of NPC in the subject are provided, with high specificity, sensitivity, and accuracy. Exemplary mutations include mutations in EMP2, IL32, EEF2KMT, CSTA, SOCS1, TESMIN, and IGFBP7 can be used to detect NPC. Mutations in IL32, DHX57, HMGN2P3, DNAJC11, EIF2AK1, FAM234A, PARPBP, ARL5A, ATPAF1, HDAC2, TACSRD2, and/or LMO4 used to achieve NPC relapse prediction. The analyte to be detected can be either RNA or protein, peptide, or fragment thereof etc. can detect NPC. High level of LY6D-positive neoplastic cells, neoplastic SPB cells reflected by RNA/protein expression of KRT16, CEBPD, CDKN1A, PGM2, and LY6D, neoplastic SPB1, SPB2 cells neoplastic SPB5 cells HDAC-mutated neoplastic SPB1 cells ATPAF1-mutated neoplastic SPB1, and low level of non-neoplastic SPB cells, non-neoplastic SPB1, and high neoplasticity of SPB cells can be used for NPC relapse prediction.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C12N 15/12 - Gènes codant pour des protéines animales
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
20.
A METHOD OF DERIVATION OF MESENCHYMAL STEM CELLS FROM MAMMALIAN PLURIPOTENT STEM CELLS
The subject invention pertains to methods of derivation of MSCs from both human or other mammal iPSCs and embryonic stem cells (ESCs) via a temporal induction of neural ectoderm in chemically defined media. In certain embodiments, the methods use a two-stage culture.
An automatic system which combines a three-branch sorter with three independently-controlled valves and corresponding collection platforms. The subgroups of droplets are alternatively sorted into three channels followed by being pumped out into PCR tubes on the platforms. Experimentally, this system can realize an accurate collection with a large working range for both pure positive samples and mixed samples with negative ones. This technology effectively dispenses a large number of droplets into small subgroups with quantitative number, which builds the basis for digital droplet microfluidics.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
G01N 15/149 - Techniques de recherche optique, p. ex. cytométrie en flux spécialement adaptées au tri des particules, p. ex. selon leur taille ou leurs propriétés
G01N 15/1492 - Techniques de recherche optique, p. ex. cytométrie en flux spécialement adaptées au tri des particules, p. ex. selon leur taille ou leurs propriétés dans des gouttelettes
CENTRE FOR ONCOLOGY AND IMMUNOLOGY LIMITED (Chine)
Inventeur(s)
Leung, Suet Yi
Yan, Hoi Ning Helen
Chan, Dessy
Abrégé
Disclosed is a method of treating cancer in a subject using cyclin-dependent kinases 4/6 inhibitors such as abemaciclib. In particular, the subject carries specific diffuse type driver pathway alterations including ARHGAP fusion and CDH1 mutation. In particular, the cancer is gastric cancer. Also provided is a system for testing drug sensitivity using gastric cancer organoid and the use of the system to identify biomarkers predicting sensitivity to CDK4/6 inhibitors in gastric cancer.
NEW LIFE MEDICINE TECHNOLOGY COMPANY LIMITED (Chine)
Inventeur(s)
Dai, Wei
Hou, Zhaozheng
Ho, Ka-Lok
Abrégé
A method for cancer diagnosis and treatment. In particular, in identifying associations between biomedical markers which is indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular nasopharyngeal cancer (NPC) metastasis after radiation therapy. The biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably radiation therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, or all markers selected from CXCR6, ASPHD2, DDX39B and AGAP9. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular nasopharyngeal cancer, is provided, as well as a corresponding method for classifying a subject and a medical decision support system.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
24.
VASCULAR NETWORK INSPIRED FLUIDIC SYSTEM FOR SPATIOTEMPORAL REGULATION OF FLUID COMPONENTS
Advanced Biomedical Instrumentation Centre Limited (Chine)
Inventeur(s)
Yu, Yafeng
Shum, Ho Cheung
Pan, Yi
Tian, Jingxuan
Guo, Wei
Abrégé
A method and apparatus for forming vascular-like channels involves liquid-in-liquid 3D printing utilizing two polymer solutions used as a printing ink and a matrix. Anionic polyacrylamide (APAM) is one of the polymer solutions and acts as the matrix material. Chitosan is the other polymer solution and acts as the printing ink. The chitosan printing ink is extruded through a print nozzle of a 3D printer onto the APAM matrix which covers the bottom of a petri dish while the nozzle is moved in a desired pattern for the channels. The chitosan and APAM polymer complexes self-assemble on the ink-matrix interface, locking chitosan polymers inside the matrix before they can spread and causing the formation of soft elastic membranous walls. The chitosan ink and APAM matrix can be removed after the polymer complex self-assembly. The printed chamber with membranous walls allows for liquid infusion to work as fluidic channels.
B29C 64/124 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective
Laboratory For Synthetic Chemistry and Chemical Biology Limited (Chine)
Inventeur(s)
Che, Chi-Ming
Zhao, Penghe
Tang, Zhou
Abrégé
Cyclometalated iron (II) complexes as photothermal transduction agents are described herein. The disclosed complexes show high structural robustness and significant absorption in the near-infrared (NIR) and visible regions. The described complexes can self-assemble to form metallosupramolecular particles, which have excellent photothermal performance and can target tumor by EPR effect. For example, the Fe NPs disclosed herein have strong near-infrared (NIR) absorbance with high photo-heat conversion efficiency of at least 30% (such as about 60%) and/or superior photothermal stability under near-infrared (e.g., 808 nm) laser irradiation. The Fe NPs may be coated with a coating agent, such as bovine serum albumin, to form a coated Fe NPs, which can further enhance the tumor accumulations and biocompatibility of the metallosupramolecular particles in vivo. The excellent photothermal performance of the Fe NPs allow them to solve the problem of low photothermal conversion efficiency associated with most existing photothermal materials.
An agent for an arrest of dental caries is a silver complex fluoride (SCF) of the structure: [Ag(1,3,5-triaza-7-phosphaadamantane)2]F, (Ag(PTA)2F). The agent effectively arrests dental caries and promotes remineralization of carious lesions. The agent results in minimal staining of teeth and tissue inflammation. The therapeutic agent can be applied selectively to a site of caries or other damaged tissue in the oral cavity.
C07F 9/6584 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle comportant des atomes de phosphore, avec ou sans atomes d'azote, d'oxygène, de soufre, de sélénium ou de tellure, comme hétéro-atomes du cycle comportant des atomes de phosphore et d'azote, avec ou sans atomes d'oxygène ou de soufre, comme hétéro-atomes du cycle comportant un atome de phosphore comme hétéro-atome du cycle
A61K 8/19 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés inorganiques
Advanced Biomedical Instrumentation Centre Limited (Chine)
Inventeur(s)
Zhang, Ruotong
Shum, Ho Cheung
Lin, Haisong
Abrégé
A droplet gripper for a polarizable droplet including a top plate formed of magnetically responsive material and movable in a defined sequence in response to a regionalized electromagnetic field. The gripper further has electret sheets downwardly depending from the top plate. The electret sheets are separated from each other and are chargeable to the same polarities so as to capture the droplet between them due to electret-induced polarization on droplet (EPD). The gripper may be included in a Multiphysics droplet robotic system for automatically manipulating and moving a liquid droplet. The system includes a programmable control matrix that generates a movable regionalized electromagnetic field through coils so as to engage the magnetic material on the top plate and move the EPD gripper and a captured polarizable drop in the defined sequence along a specific path as well as to achieve other microfluidic operations according to a control matrix program.
A series of highly rigid and highly luminescent cyclometalated tetradentate ligand-containing gold (III) compounds is designed and synthesized. The cyclometalated tetradentate ligand-containing gold (III) compounds can be used as light-emitting material for fabrication of light-emitting devices. The cyclometalated tetradentate ligand-containing gold (III) compounds can be deposited as a layer or a component of a layer using a solution-processing technique or a vacuum deposition process. The cyclometalated tetradentate ligand-containing gold (III) compounds are robust and can provide electroluminescence with high efficiency and brightness. More importantly, vacuum-deposited OLEDs demonstrate high operational stabilities with long operational half-lifetimes of over 188,000 hours at 100 cd m-2.
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
H05B 33/14 - Sources lumineuses avec des éléments radiants ayant essentiellement deux dimensions caractérisées par la composition chimique ou physique ou la disposition du matériau électroluminescent
29.
LUMINESCENT GOLD(III) COMPOUNDS WITH THERMALLY STIMULATED DELAYED PHOSPHORESCENCE (TSDP) PROPERTY FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION
Described herein are a novel concept of thermally stimulated delayed phosphorescence (TSDP) to harvest light emission from the higher energy triplet excited state via the up-conversion from the lowest-energy triplet excited state by efficient spin-allowed reverse internal conversion as well as the development of TSDP emitters, as exemplified by a novel class of gold(III) compounds with TSDP properties and methods of making and using said compounds. The gold(III) compound includes a triazine-containing cyclometalating tridentate ligand and one auxiliary ligand, both coordinated to a gold(III) metal center. The gold(III) compounds disclosed herein can be used as light-emitting material for fabrication of OLEDs.
H10K 50/12 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL] comprenant des dopants
H10K 71/13 - Dépôt d'une matière active organique en utilisant un dépôt liquide, p. ex. revêtement par centrifugation en utilisant des techniques d'impression, p. ex. l’impression par jet d'encre ou la sérigraphie
H10K 71/16 - Dépôt d'une matière active organique en utilisant un dépôt physique en phase vapeur [PVD], p. ex. un dépôt sous vide ou une pulvérisation cathodique
The present invention relates to methods for predicting the recurrence risk of hepatocellular carcinoma (HCC). Specifically, it proposes a deep learning model capable of integrating information from different phases of CT images and clinical data to predict the risk of HCC recurrence within 1 to 5 years after treatment. Experimental results demonstrate that these models outperform traditional prediction methods based on histological microvascular invasion (MVI) in predicting HCC recurrence risk.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
HYDROGEL-BASED DELIVERY SYSTEM FOR INDUCTION OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES AND AUGMENTATION OF IMMUNE CHECKPOINT BLOCKADE AND METHODS THEREOF
Provided is a system for drug delivery utilizing hydrogel to deliver biologically active agents to stimulate mature intratumoral tertiary lymphoid structure formation and augment immune check point blockade. Provided herein is an injectable hydrogel that can stimulate the formation of immune structures within tumors, improving cancer prognosis and treatment response. Provided is a method of treating cancer. Also provided is a method of making the drug delivery system.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
32.
DATA-BASED PERSONALIZED SITE-SPECIFIC CARE ADVISING MODEL POWERED WITH ARTIFICIAL-INTELLIGENCE
Described is a computer-implemented system (CIS), a computer-implemented method (CIM), and/or or machine learning algorithm (MLA) that generates anatomically site-specific advice on topical anatomy healthcare, such as oral hygiene care based on images initially generated using a mobile phone (e.g., a smart phone) or other hand-held devices. The CIS, CIM, or MLA contains a generative artificial intelligence (AI) platform operably linked to a graphical user interface (GUI) and a discriminative AI platform. The discriminative AI platform generates topical, anatomical images contain the state of health of specific sites on the anatomy, while the generative AI platform generates anatomically site-specific health-based advice based on the image generated by the discriminative AI platform, and transmits the advice to the GUI. The disclosed CIM, CIS, or MLA provides new platforms that utilize AI to provide, automatically and instantaneously, personalized oral hygiene care.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
33.
SELF-DILUTING MICROFLUIDIC DEVICE FOR RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTS
Advanced Biomedical Instrumentation Centre Limited (Hong Kong)
Centre for Virology, Vaccinology and Therapeutics Limited (Hong Kong)
Inventeur(s)
Ul Hassan, Sammer
Shum, Ho Cheung
To, Kai-Wang Kelvin
Wat, Ka Hei
Abrégé
The present invention relates to a SDFAST (Self Dilution for Faster Antimicrobial Susceptibility Testing), which is a microfluidic device that can perform self-dilution and does not require any pumps or valves to accomplish multiplexed microfluidic processes. SDFAST is designed using AutoCAD and fabricated using micro-milling machine. It consists of two polymethyl methacrylate (PMMA) rectangular plates which are in contact throughout the operation. The first plate is the bottom one that serves as lines of wells. The second plate is the top one that acts as a lid and seals the system. The second plate has complementary designs that echo the wells in the first plate, which allows fluidic channels to be formed.
A method of ligand-induced regional modification of a perovskite film of perovskite optoelectronic device can include generating a ligand atmosphere, exposing a perovskite optoelectronic device in the ligand atmosphere, and removing the perovskite optoelectronic device from the ligand atmosphere. Methods for improving the performance and stability of perovskite optoelectronic devices are performed by using a ligand-induced modification of complete devices at room temperature. This post-device treatment, completely separated from the fabrication process of common perovskite optoelectronic devices, provides a general strategy to improve the stability of different completed perovskite optoelectronic devices (i.e., perovskite solar cells, perovskite light-emitting diodes, and photodetectors) without introducing any undesirable impurities during device fabrication.
H01G 9/00 - Condensateurs électrolytiques, redresseurs électrolytiques, détecteurs électrolytiques, dispositifs de commutation électrolytiques, dispositifs électrolytiques photosensibles ou sensibles à la températureProcédés pour leur fabrication
H10K 30/30 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des hétérojonctions de masse, p. ex. des réseaux interpénétrés de domaines de matériaux donneurs et accepteurs
A hot end (16) for a fused deposition modeling (FDM) printer has two entrances for low-fluidity materials that may differ from each other by color and/or structure. Two separate channels (21a, 21b) of the hot end (16) lead from the entrances to a common end at a central tube (25). The two channels (21a,21b) are in the form of two special angle-skewed tubes that meet at their ends and that narrow gradually from the extruders (19') toward their ends. The central tube (25) extends from the ends of the channels (21a, 21b) to an nozzle (26). An SK type static mixer (24) is located in the central tube (25) and a heating unit (11) surrounds the hot end (16). A controller (15) operates the two extruders (19') that supply the low-fluidity materials to the two entrances of the hot end (16) in such a way as to produce ceramic (e.g., zirconia) objects that have 3D color and structural gradients.
Disclosed is an anti-caries compound, composition with antimicrobial and/or remineralizing properties and methods of using the compound and composition. The anti-caries compound is synthetic peptide Gallic-Acid-Polyphemusin-1 (GAPI) that is useful to manage dental hygiene and oral infections. Method of making a highly stable and purified form of GAPI is also disclosed. Also disclosed are the minimum inhibitory concentration and minimum bactericidal concentration against common oral pathogens.
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A vapor deposition system is described. The vapor deposition system includes a reaction chamber and a reactant delivery subsystem coupled with the reaction chamber. The reaction chamber is configured to retain a substrate therein. The reactant delivery subsystem includes inlets, a pre-reaction region, and outlets. The inlets receive precursors and chalcogen precursor(s). The pre-reaction region is configured to receive the precursors from a portion of the inlets and to react at least a portion of the precursors to form modified precursor(s). The modified precursor(s) are more thermally stable than metal-containing precursor(s) of the precursors used to form the modified precursor(s). The outlets are coupled with the reaction chamber and the pre-reaction region. The outlets separately provide the modified precursor(s) and the chalcogen precursor(s) to the reaction chamber. The modified precursor(s) and the chalcogen precursor(s) react and form a chalcogen film on the substrate in the reaction chamber.
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p. ex. borures, carbures, nitrures
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
38.
BIOMIMETIC INTRAOCULAR DRUG DELIVERY SYSTEM FOR TREATMENT OF RETINOBLASTOMA AND METHODS THEREOF
Provided is a drug delivery system comprising an ophthalmic composition for administration. The composition comprises nanoparticles comprising a core and an outer surface. The core comprises drugs and a carrier and the outer surface comprises a membrane derived from an ocular tumor cell. Also provided is a method of treating an ocular disease or condition using the nanoparticles. Also provided is a method of making the drug delivery system.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A vapor deposition system is described. The vapor deposition system includes a reaction chamber and a reactant delivery subsystem coupled with the reaction chamber. The reaction chamber is configured to retain a substrate therein. The reactant delivery subsystem includes a inlets, a pre-reaction region, and outlets. The inlets receive precursors and chalcogen precursor (s). The pre-reaction region is configured to receive the precursors from a portion of the inlets and to react at least a portion of the precursors to form modified precursor (s). The modified precursor (s) are more thermally stable than metal-containing precursor (s) of the precursors used to form the modified precursor (s). The outlets are coupled with the reaction chamber and the pre-reaction region. The outlets separately provide the modified precursor (s) and the chalcogen precursor (s) to the reaction chamber. The modified precursor (s) and the chalcogen precursor(s) react and form a chalcogen film on the substrate in the reaction chamber.
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p. ex. borures, carbures, nitrures
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
H01L 31/032 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des composés non couverts par les groupes
40.
HIGHLY STABLE SOLUTION-PROCESSED TRANSPARENT ELECTRODE BASED ON METAL NANOWIRE NETWORK AND POLYMERS
A method of integrating a solution-processed transparent electrode based on a metallic nanowire network and polymers is provided. The method includes forming at least one metallic network on an underlying substrate via a solution process comprising a plurality of metal nanowires and a plurality of junctions where the metal nanowires meet; forming a gap filling layer on the metallic network to form a complex of metallic network and polymer; and drying the complex of metallic network and polymer, wherein the metallic network and polymer are connected to each other at least by chemical bonding.
Provided are methods and compositions for treatment, screening, diagnosis and prognosis of hepatocellular carcinoma with extrahepatic metastasis. Provided herein are methods and compositions for treatment, screening, diagnosis and prognosis of metastatic cancers. Also provided are monoclonal antibodies and compositions for the treatment of cancers. Provided herein is therapeutic target for the treatment of cancers or as a marker for cancers.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A method for detecting sCDCP1 in a bodily fluid of a subject, wherein the subject is selected for early pharmacological and/or lifestyle intervention for nonalcoholic steatohepatitis (NASH), when: (a) the level of sCDCP1 detected in the bodily fluid of the subject is elevated compared to the average level of sCDCP1 in the bodily fluid of subjects not suffering from NASH and/or (b) a numerical score calculated by using the level of sCDCP1 in an algorithm is elevated compared to the numerical score calculated by using the average level of sCDCP1 in the bodily fluid of subjects not suffering from NASH in the algorithm of sCDCP1. A method for treating a subject having NASH, comprising treating the subject with a therapy that reduces CDCP1 expression.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
43.
INTEGRATED ANALYSIS METHOD AND APPARATUS FOR MULTIMODAL RETINAL GANGLION CELL DATA
Provided are an integrated analysis method and apparatus for marking multimodal retinal ganglion cell (RGC) data of central nervous system cell aging. The method uses an aged RGC as a biomarker of the central nervous system cell aging, and comprises: applying an ETDRS grid to a reconstructed plan view of a macular region in an OCT retinal thickness image, so as to divide the plane view into a plurality of regions, wherein the OCT thickness image comprises thickness and volume data values of five different retinal layers; grouping the plurality of regions and determining the average thickness and volume data distribution of each region to measure the abundance of RGCs; using a posterior pole module to record an OCTA image and performing fine stratification to obtain a retinal microvascular change in the OCTA image; and obtaining 103 hexagonal mfERG reports where pERG and ETDRS grids have a same center at a macula. On the basis of the obtained information, the histological and functional analysis of the RGCs is combined with the precise position distribution and corresponding blood supply microvascular changes to provide a non-invasive early detection analysis module that reflects the health of the RGCs.
Centre for Oncology and Immunology Limited (Chine)
Inventeur(s)
Chung, Yik Sham Clive
Li, Ying Ki Jason
Koo, Tin Yan
Yan, Hoi Ning Helen
Abrégé
RhoA inhibitors that can covalently bind RhoA are described herein. The disclosed RhoA inhibitors show improved inhibitory efficacy (i.e., an IC50 value down to about 400 nM). Further, the disclosed RhoA inhibitors can specifically bind RhoA over other GTPases, such as other Ras GTPases (e.g., K-Ras and N-Ras) and particularly other Rho GTPases (e.g., Cdc42 and Rac1). The combination of high RhoA inhibitory efficacy and high RhoA specificity of the disclosed RhoA inhibitors allow these compounds to show high cytotoxicity and anti-metastatic effects in cancer cells, with negligible toxicity in normal cells, in vitro and in vivo. Pharmaceutical compositions containing the RhoA inhibitors and methods of using the RhoA inhibitors or pharmaceutical composition thereof for treating cancer are also described.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
45.
IRON COMPLEXES FOR ENANTIOSELECTIVE CIS DIHYDROXYLATION OF ALKENES
Laboratory for Synthetic Chemistry and Chemical Biology Limited (Chine)
Inventeur(s)
Che, Chi Ming
Wang, Tingting
Abrégé
Methods for asymmetric cis-dihydroxylation (“AD”) of styrenes and conjugated dienes to produce cis-diols of styrene and conjugated diene or tetraols of conjugated diene with high yield (i.e., a yield ≥30%) and high enantioselectivity (i.e., an enantiometric excess ≥60%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst. The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a styrene or conjugated diene, one or more iron-based catalyst(s), an oxidant, and a solvent, and where the product contains a cis-diol or tetraol.
C07C 29/48 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par des réactions d'oxydation avec formation de groupes hydroxyle
46.
System and Method for Simulating Intervertebral Discs
The present invention provides a method of simulating an intervertebral disc, comprising: automatically segmenting a medical image of a spine based on a pre-trained model so as to obtain different intervertebral disc segmentations; and biomechanical modelling under multiple motions for the different intervertebral disc segmentations so as to obtain dynamic properties of the intervertebral disc.
Metallo-complex compounds and pharmaceutical compositions thereof are described herein. The metallo-complex compounds and pharmaceutical compositions can be use in treating infections in a subject in need thereof. The infections can be bacterial infections, such as multidrug resistant (MDR) bacterial infections.
C07D 501/46 - Radicaux méthylène, substitués par des atomes d'azoteLeurs lactames avec le groupe carboxyle-2Radicaux méthylène substitués par des hétérocycles contenant de l'azote lié par l'atome d'azote du cycleLeurs composés quaternaires avec le radical amino-7 acylé par des acides carboxyliques contenant des hétérocycles
C07D 501/00 - Composés hétérocycliques contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. des composés contenant un système cyclique de formule , p. ex. céphalosporinesCes systèmes cycliques étant ultérieurement condensés, p. ex. condensés en positions 2, 3 avec des hétérocycles contenant de l'oxygène, de l'azote ou du soufre
A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine
Centre for Oncology and Immunology Limited (Hong Kong)
Inventeur(s)
Wong, Siu Lun
Chu, Hoi Yee
Abrégé
A machine learning-based top variant identification pipeline method and systems for engineering genome editing proteins are provided. The method includes steps of performing zero-shot predictions by a zero-shot predictor together with a clustered-based sampling (CS) or Top regime method with wild-type (WT) being added to training data for low-N training data preparation; performing machine learning-assisted directed evolution (MLDE) predictions based on the training data prepared; and performing multi-round sampling of the CS/MLDE predictions, in which the wild type is added in a first-round sampling of the multi-round sampling. The zero-shot predictor is based on an arDCA method, an EVmutation method, an EvoEF method or a MSA method. The performance of the zero-shot predictor is evaluated based on performance metrics including Spearman's correlation (rho) and/or top 5% overlaps (overlap_5).
Centre for Virology, Vaccinology and Therapeutics Limited (Chine)
Inventeur(s)
Yan, Bingpeng
Chan, Jasper Fuk-Woo
Kao, Yi Tsun Richard
Yuan, Shuofeng
Shum, Cynthia Cheuk Ying
Abrégé
Host-targeting antiviral agents against conserved phosphatidic acid phosphatase (PAP) pathways that act as broad-spectrum treatment strategies for different coronaviruses, such as variants of SARS-COV-2, have been developed. Compositions of anti-coronavirus agent(s) that acts via the host PAP pathway and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. An exemplary anti-coronavirus agent that acts via the PAP pathway is propranolol. Compositions of propranolol and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. In some forms, the compositions and methods treat or prevent one or more symptoms associated with infection by SARS-COV-2 wild type, Delta variants, Omicron variants and MERS-COV in a subject in need thereof.
Centre for Oncology and Immunology Limited (Chine)
Inventeur(s)
Wong, Carmen Chak Lui
Wong, Chun Ming
Chin, Wai Ching
Yuen, Wai Hin
Abrégé
Compositions including recurrent hepatocellular carcinoma (HCC) model generating systems are disclosed. The HCC model generating system contains a CRISPR-Cas expression vector, a transposase expression vector, and a transposon expression vector. Also provided is a non-human animal model of recurrent HCC containing genetic modifications introduced by integration of the model generating system into target liver cells of target animals. Upon stable integration, the model generating system modifies expression of Tp53 and expresses the oncogene in the target liver cells of the target animal, resulting in the development of a HCC tumors in the liver. Methods of using the non-human animal model of recurrent HCC are also provided. The non-human animal model of recurrent HCC can be used for research purposes such as investigating the molecular and genetic mechanisms underlying recurrent HCC tumor development, identifying potential therapeutic targets, and evaluating/screening potential compounds for the treatment of recurrent HCC.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
51.
HUMAN PROTECTIVE NEUTRALIZING AND NON-NEUTRALIZING ANTIBODIES AND THEIR USE AGAINST INFLUENZA VIRUSES
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE UNIVERSITY OF HONG KONG (Chine)
Inventeur(s)
Wu, Xueling
Jia, Manxue
Ho, David, D.
To, Kelvin, Kai-Wang
Yuen, Kwok-Yung
Shapiro, Lawrence
Morano, Nicholas, C.
Lu, Hong
Abrégé
Disclosed herein are vectors, synthetic antibodies, and methods of producing and using the same, comprising at least one polynucleotide sequence encoding an antibody or fragment thereof, wherein a variable heavy chain domain of the antibody or fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7, and a variable light chain domain of the antibody or fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8.
NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Zhang, Shuang
Guan, Fuxin
Dai, Qing
Guo, Xiangdong
Abrégé
Provided is a method for compensating for loss in wave propagation, comprising: obtaining real frequency responses on the basis of a measurement result of wave propagation; selecting a complex frequency on the basis of the frequency of a wave and the dielectric constant of a medium so as to at least partially counteract the imaginary part of an in-plane wave vector in the wave propagation; and on the basis of a plurality of real frequency responses and the complex frequency, obtaining a complex frequency response to compensate for loss in the wave propagation.
The present invention relates to a welding assembly for packaging of a power semiconductor module. The welding assembly comprises: a first component, the outermost layer on a first side of the first component being a non-copper metal layer; a second component, a first copper layer being arranged on a first side of the second component; and a connecting copper layer, wherein two sides of the connecting copper layer are respectively connected to the non-copper metal layer and the first copper layer to form a first interface and a second interface, such that the first component and the second component are fixed together, and the average grain size of the connecting copper layer is in the range of 35-400 nm. The present invention further provides a welding assembly used for packaging of a semiconductor chip and relating to a plurality of components, and a method for producing the welding assembly for packaging of a power semiconductor module.
H01L 21/60 - Fixation des fils de connexion ou d'autres pièces conductrices, devant servir à conduire le courant vers le ou hors du dispositif pendant son fonctionnement
54.
MULTI-WELL DEVICE FOR LARGE-SCALE, HIGH THROUGHPUT FORMATION OF MICROTISSUES AND ITS USE
ADVANCED BIOMEDICAL INSTRUMENTATION CENTRE LIMITED (Chine)
Inventeur(s)
Chan, Pui Barbara
Lau, Yu Ting
Hassan, Sammer Ul
Shum, Ho Cheung
Abrégé
Described is a device for large-scale, high throughput, and rapid fabrication of microtissues. The device is designed as an invertible insert or a hanging insert, suitable for inversion and placement inside a single-compartment tissue culture plate. Further, the device has a three-dimensional support and contains a two-dimensional array of microwells with round-bottom cavities. The device facilitates the formation of multiple microtissues, including both cell aggregates and matrix-incorporated microtissues, through a single deposition process. Features of the device allow harvesting of microtissues via low-speed centrifugation.
The purpose of the present disclosure is to perform communication and channel estimation by using a multi-functional signal in a wireless communication system. A method for operating a first device may include the steps of: transmitting a first signal having a non-coherent detectable structure; transmitting first configuration information related to sounding to a second device; receiving a second signal on the basis of the first configuration information; transmitting second configuration information related to channel estimation to the second device; and transmitting a third signal to the second device on the basis of the second configuration information. The second configuration information is based on an antenna position of the second device, the antenna position being estimated on the basis of the first signal and the second signal, and may include a range of at least one basis vector included in a dictionary.
DONGGUAN INSTITUTE OF OPTO-ELECTRONICS, PEKING UNIVERSITY (Chine)
SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (Chine)
Inventeur(s)
Chu, Zhiqin
Jing, Jixiang
Lin, Yuan
Wang, Qi
Wang, Zhongqiang
Li, Kwai Hei
Abrégé
A method for scalable fabrication of ultraflat polycrystalline diamond membranes, comprising: (1) growing a polycrystalline diamond membrane on a growth substrate having diamond seeds on the surface thereof using a chemical vapour deposition method; (2) cutting off at least a portion of the substrate after growth, forming a boundary at the cut where the polycrystalline diamond membrane is bonded to the growth substrate; (3) sticking a peeling tape; and (4) pulling the peeling tape to peel the polycrystalline diamond membrane off the surface of the growth substrate to expose the nucleation surface of the polycrystalline diamond membrane, wherein the exposed nucleation surface has a roughness less than the roughness of the grown surface. By flipping the nucleation surface of the grown polycrystalline diamond membrane, develops a novel and facile approach for fabricating affordable, scalable, ultraflat and transferable polycrystalline diamond membranes with great potential for practical applications.
C23C 16/511 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement au moyen de décharges électriques utilisant des décharges à micro-ondes
57.
DEVICE AND METHOD FOR ESTIMATING NEAR-FIELD CHANNEL IN WIRELESS COMMUNICATION SYSTEM
The present invention is for estimating a near-field channel in a wireless communication system. This method for operating a terminal may comprise the steps of: receiving first configuration information related to sounding from a base station; transmitting a sounding signal on the basis of the first configuration information; receiving second configuration information related to channel estimation from the base station; receiving a downlink reference signal from the base station on the basis of the second configuration information; and performing the channel estimation on the basis of the downlink reference signal.
H04B 17/373 - Prédiction des paramètres de qualité d’un canal
H04L 5/00 - Dispositions destinées à permettre l'usage multiple de la voie de transmission
H04W 72/23 - Canaux de commande ou signalisation pour la gestion des ressources dans le sens descendant de la liaison sans fil, c.-à-d. en direction du terminal
H04B 7/06 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
H04B 7/08 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station de réception
H04W 64/00 - Localisation d'utilisateurs ou de terminaux pour la gestion du réseau, p. ex. gestion de la mobilité
58.
Plasmonic Heating Assisted Interfacial Polymerization for Reverse Osmosis Membrane Fabrication
An interfacial plasmonic heating intensified IP reaction (IPH-IP) is used to fabricate highly permeable and selective polyamide RO membranes. Silver nanoparticles (AgNPs) are introduced to the IP reaction interface to serve as nano-heat generators under light illumination. The coupling of generated nano-heat rapidly promotes the interfacial temperature, thereby boosting the formation of extensively “nano-foamed” polyamide with prominent nanovoids and high crosslinking degree. These features enable the resulting RO membrane to achieve a superior combination of water permeance (3.4 L m−2 h−1 bar−1) and NaCl rejection (99.7%). This outstanding separation performance further enables the membrane to efficiently remove a wide spectrum of toxic contaminants frequently found in different water sources, revealing huge potential for various water treatment applications. In addition, the resulting RO membrane demonstrates efficient desalination of real seawater, producing clean water with high quality that far exceeds those of benchmarking commercial membranes.
The present disclosure is for acquiring channel information in a wireless communication system. An operation method of a terminal may comprise the steps of: receiving a first signal; generating information related to a channel by using the first signal; transmitting a second signal including feedback information related to the channel; and receiving a third signal transmitted on the basis of the feedback information. The feedback information includes information related to the distance between channel information and each portion of the first signal, and the first signal may have a structure supporting at least one operation among transferring information to another terminal and sensing an object.
G01S 13/00 - Systèmes utilisant la réflexion ou la reradiation d'ondes radio, p. ex. systèmes radarSystèmes analogues utilisant la réflexion ou la reradiation d'ondes dont la nature ou la longueur d'onde sont sans importance ou non spécifiées
H04B 7/06 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
National Center for Nanoscience and Technology (Chine)
Inventeur(s)
Zhang, Shuang
Guan, Fuxin
Zeng, Kebo
Dai, Qing
Guo, Xiangdong
Abrégé
A method for enhancing characteristic signals by synthesizing multiple frequency waves is provided, which includes: obtaining real frequency responses based on the measurement results of spectral signals; selecting complex frequencies to at least partially compensate for spectral line broadening caused by losses; and obtaining complex frequency responses based on multiple real frequency responses and the selected complex frequencies to enhance the characteristic signals.
H03L 7/16 - Synthèse de fréquence indirecte, c.-à-d. production d'une fréquence désirée parmi un certain nombre de fréquences prédéterminées en utilisant une boucle verrouillée en fréquence ou en phase
61.
Method and apparatus for Multi-Modal Polarization Holographic Spectrometry for Material Analysis
A two-dimensional spectrum recording apparatus has a source of collimated laser light impinging on a sample on a plate. The light passing through the sample forms an object wave and the light not passing through the sample forming a reference wave, which interfere with each other to form a holographic image at the plate. A beam splitter receives the collimated laser light from the sample and forms separate first and second light beams. A linear polarizer receives the first beam and passes it to a polarization camera having a Full Stokes mask. The camera records the light that passes through the Stokes mask. A slit aperture receives the second beam and transforms it into a slit of light that is applied to a diffraction grating. A diode array receives the second beam from the diffraction grating and forms a light spectrum that is recorded.
The purpose of the present disclosure is to generate a multi-functional signal in a wireless communication system. This method for operating a device may comprise the steps of: generating information bits; generating at least one codeword by encoding the information bits; generating at least one symbol corresponding to at least a part of the at least one codeword; and transmitting the at least one symbol.
The subject invention pertains to a novel poly(diallyldimethylammonium) fluoride (PDDAF) compound that provides a restorative material to arrest dental caries, remineralize carious lesions, and inhibit bacterial growth.
C08G 61/12 - Composés macromoléculaires contenant d'autres atomes que le carbone dans la chaîne principale de la macromolécule
A61K 6/20 - Revêtements de protection pour dents naturelles ou artificielles, p. ex. scellements, revêtements colorés ou vernis
A61K 8/84 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 31/787 - Polymères contenant de l'azote contenant des hétérocycles ayant l'azote comme hétéro-atome d'un cycle
A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p. ex. dentifricesBains de bouche
64.
POLYMERSOME NANOPARTICLES EXHAUSTING INTRACELLUAR AMINO ACID FOR CANCER THERAPY AND METHODS THEREOF
Disclosed are polymersome nanoparticles that comprise a combination of drugs: (i) a ubiquitin-proteasome system (UPS) inhibitor; and (ii) a macropinocytosis inhibitor. Also disclosed is a method of treatment of cancer using the nanoparticles. Disclosed is a method of treatment of tumor having nutrient-deprived microenvironment, such as deficient in amino acids. The disclosure is directed to a combination of drugs for starvation of tumor cells comprising the use of nanoparticles which inhibits degradation of proteins in the tumor cells and prevents internalization of proteins into the tumor cells. Also provided are compositions and methods for affecting cell proliferation, metabolism or sensitization, including proteasome inhibitor therapy for the treatment of disease caused by deregulation of ubiquitin-proteasome systems, in a cell or subject.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
CENTRE FOR ONCOLOGY AND IMMUNOLOGY LIMITED (Chine)
UNIVERSITY HEALTH NETWORK (Canada)
Inventeur(s)
Mak, Tak Wah
Zheng, Chunxing
Abrégé
The T-cell receptor (TCR) plays a crucial role in the adaptive immune response by recognizing specific antigens. In the context of cancer immunotherapy, TCR sequences can be engineered to target specific tumor antigens. In this study, hepatocellular carcinoma (HCC) was modeled in mice by combining genetic alterations recurrently observed in the human disease, and identified HCC-specific TCRs using single-cell TCR-seq. TCR convergence was observed across HCC-bearing mice, indicating that TCRs specific for HCC antigens elicit the expansion of CD4+ T cells. To further elucidate the function of this HCC-specific TCR, TCR-expressing vectors were designed and built, which can be used for various in vitro and in vivo applications, including identifying the specific peptide sequence that the TCR recognizes, manufacturing TCR-engineered T cells, studying T cell function, and screening potential immunotherapies. The findings have important implications for the development of T cell-based cancer immunotherapies.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
An electronic reader for electro-chemical transistors (OECT) includes a potential output control module that controls the Vd, Vs, and Vg for the OECT under test, a high accuracy current monitor module which contains a transimpedance amplifier (TIA) used to control the output voltage and convert the input channel current Ids into a voltage value. A microcontroller (MCU) that controls the working sequences of the TIA so as to realize the specific characterization mode and enable an adjustable output voltage range. The MCU further controls a programmable sampling rate of up to 200 k samples per second (SPS) with low noise by down-sampling the base rate, convolution processing it and interpolating it back to ah high frequency, but without the noise. The device is small enough to be worn by a user and its output is sent to a mobile device for reading.
The present invention provides a tensegrity joint comprising: a first inner structure having a first frame and a first strut extending orthogonally from the first frame; a second inner structure having a second frame and a second strut extending orthogonally from the second frame; at least three actuation tendons, each being fixed at a respective hole at the first frame and being guided and allowed to slide through a respective hole at the second frame; a central tendon connecting an apex of the first strut and an apex of the second strut such that the central tendon is in balance with the pulling forces exerted by the at least three actuation tendons; and an outer elastic protection sheath configured to wrap on a cylindrical surface between the first and second inner structures.
The present invention relates to the technical field of construction waste treatment. Provided is an on-site intelligent sorting method for construction waste. The method comprises: S10, identifying waste components, and quantifying the proportion of inert material in construction waste; S20, by means of a computer vision method, acquiring visual difference features between the inert material and non-inert material; S30, performing mechanical screening, wherein the construction waste is screened by means of a mechanical screening module; S40, on the basis of precise sorting by a robot, performing detection on waste on a conveyor belt by means of waste detection driven by machine vision, then performing waste positioning, and, according to the results of waste detection and positioning, performing accurate sorting by using multiple robotic arms. The advantages of the present invention comprises: the described method is suitable for compact construction site scenes, the required space for installation and deployment is small, and an intelligent solution is provided for construction waste classification at compact sites.
B07B 9/00 - Combinaisons d'appareils à cribler ou tamiser ou à séparer des solides par utilisation de courants de gazDisposition générale des installations, p. ex. schéma opératoire
B03C 1/30 - Combinaisons avec d'autres dispositifs, non prévues ailleurs
69.
SMART MEASUREMENT METHOD FOR CONSTRUCTION WASTE COMPONENTS
wastewasteinertnon-inertnon-inert; and S30, establishing a general linear equation. The beneficial effects of the present invention are as follows: a construction waste mixture conforming to a classification standard can be identified quickly and accurately at a low cost, and construction waste having low classification and recycling value is excluded, thereby reducing the time cost and mechanical cost, and improving the treatment efficiency of the construction waste.
222, and wherein the iron-based metal complex has undergone a pulsed laser treatment for increasing catalytic surface area, number of catalytic sites and/or catalytic efficiency of the iron-based metal complex when compared with untreated iron-based metal complex before the pulsed laser treatment.
Disclosed is an automated method for evaluating the ZP-binding capability of spermatozoa according to their morphological features in assisted reproduction using deep learning. Also provided is a method of predicting fertilization success in clinical assisted reproduction based on the ZP-binding capability of spermatozoa.
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
An ambient noise differential adjoint tomography system(l) is provided. The system(l) comprises seismic wave recording devices(101,102,103) and a processor) 100). The processor) 100) indicates three of the seismic wave recording devices(101,102,103) as a source(lOl), a first receiver) 102), and a second receiver) 103), and the source(lOl) and the first and second receivers (102, 103) are arranged as a linear array, and the first and second receivers(102,103) are positioned nearby each other. The processor) 100) receives seismic noise and obtain a noise interferometry, computing synthetic dispersive surface wave signals, generating a differential adjoint tomography based on observed dispersive surface wave from the noise interferometry. The processor) 100) estimates a shear wave velocity from the differential adjoint tomography, using the estimated tomography to estimate the characteristic of the region, and the processor) 100) provide a diagram with characteristic of the region through a display or printer.
CENTRE FOR ONCOLOGY AND IMMUNOLOGY LIMITED (Chine)
UNIVERSITY HEALTH NETWORK (Canada)
Inventeur(s)
Mak, Tak Wah
Zheng, Chunxing
Snow, Bryan Edward
Abrégé
Provided is a reliable and convenient approach to achieve precise control of gene expression in the liver in vivo. The methods generally combine a doxycycline-inducible gene expression system with a Sleeping Beauty transposon vector and hydrodynamic injection, enabling efficient integration of a controllable gene expression system into the genome of hepatocytes. The doxycycline-inducible system generally allows for precise and reversible control of gene expression. In some forms, a combination of gene alterations and overexpression of Myc leads to the development of HCC in animals. The method can also use a vector that allows for the inducible expression of a tumor antigen. The method can also induce tumor antigen-specific T-cell immune responses, providing a potent tool for the development of targeted therapies for HCC.
A system and devices provide for accurate localization of orthopedic implants based on magnetic tracking approach (MTA) technology and without radiation. The system includes at least one magnetic beacon that is joined to an orthopedic screw/implant fixed to a patient's spine. A detector in the form of a magnetic sensor array detects the magnetic field from the beacon and produces an electrical signal in response thereto. A computer using a multi-objective magnetic location algorithm tracks the spatial position and movement of the beacon based on the electrical signal, and hence tracks the patient's spine.
A hypoventilation physical model is provided. Particularly the physical model includes brainstem and cerebral organoids derived from pluripotent stem cells (PSCs) having a PHOX2B gene mutation. This mutation includes polyalanine repeat expansion mutations (PARMs), specifically 5-PARM, 7-PARM, and 13-PARM. These PARMs occur within a 20-alanine (20-Ala) polyalanine tract in exon 3 of the PHOX2B gene. The physical model provides a platform for studying impaired ventilatory responses and associated neuronal defects, offering a valuable tool for drug screening and the development of therapeutic strategies for hypoventilation syndromes.
An ultrafast wide-field quantum sensing device using a neuromorphic event-based vision sensor includes a laser generating a laser beam; a dichroic mirror directing the laser beam onto a diamond sample and passing the laser beam reflected from the diamond, and an event camera receiving from the dichroic mirror the beam reflected from the diamond. A source of microwave energy applied to the diamond. A pulse generator synchronizes the microwave source and the event camera to create CW-ODMR measurements, wherein trigger pulses from the pulse generator are applied to the camera and microwave source. The optically detected magnetic resonance (ODMR) resonance frequency is determined based on the CW-ODMR measurements.
G01R 33/32 - Systèmes d'excitation ou de détection, p. ex. utilisant des signaux radiofréquence
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
G01N 22/00 - Recherche ou analyse des matériaux par l'utilisation de micro-ondes ou d'ondes radio, c.-à-d. d'ondes électromagnétiques d'une longueur d'onde d'un millimètre ou plus
G01R 33/26 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique pour la mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques utilisant le pompage optique
77.
CHOLINERGIC IMMUNOTHERAPY FOR THE TREATMENT OF LIVER CANCER
CENTRE FOR ONCOLOGY AND IMMUNOLOGY LIMITED (Chine)
Inventeur(s)
Mak, Tak Wah
Zheng, Chunxing
Abrégé
It has been discovered that the presence of cholinergic T cells is important for an effective immune response to hepatocellular carcinoma (HCC). The results demonstrate a novel aspect of the regulation of cancer immunosurveillance by an immune cell-derived neurotransmitter and shed light on its role in supporting cells mounting anti-tumor responses. Disclosed are methods of treating HCC in a subject in need thereof. Generally, the methods involve treating the subject with a therapy effective to increase the level of acetylcholine in T cells. Also disclosed are method where the subject is treated with anti-PD-1 immunotherapy when the determined level of cholinergic T cells in the subject is high or refraining from treating the subject with anti-PD-1 immunotherapy when the determined level of cholinergic T cells in the subject is low.
The subject invention pertains to photocleavable prodrugs that facilitate the controllable drug delivery to the target sites modulated by light irradiation, including a photocleavable boron-dipyrromethene-derived prodrug and a dye, which achieved both high prodrug loading capacity (˜99%) and efficient light-triggered prodrug activation. The incorporation of the dye not only stabilized the nanoparticles and contributed tumor targeting as usual. but also exhibited degradation after light irradiation and in-situ monitoring of nanoparticle dissociation by fluorescent imaging.
A quantum-inspired parallel annealing method that enables full parallelism and improves solution quality, resulting in significant speed and energy improvement when implemented in analog memristor crossbars. Tasks are experimentally solved, including unweighted and weighted Max-Cut and traveling salesman problem using an integrated memristor chip. The method claimed herewith effective exploits the natural parallelism, analog conductance states and all-to-all connection provided by memristor technology, and therefore demonstrates significant improvements in time- and energy-efficiency compared to previous simulated annealing and Ising machine implemented on other technologies, having a large potential for solving complex optimization problems with greater efficiency.
Advanced Biomedical Instrumentation Centre Limited (Hong Kong)
Inventeur(s)
Xu, Lizhi
Liu, Hongzhen
Abrégé
A mechanoionic current generator comprising: a working electrode including an activated carbon cloth; and a counter electrode including a raw carbon cloth and a hydrogel; wherein the hydrogel has a plurality of flexible and asymmetrically shaped structures; and the working electrode has a surface immersed in the hydrogel and provided with a plurality of oxygen-containing functional groups. The ionic current generation mechanism of the current generator is naturally compatible with living organisms and living hydrogels, as exemplified by a self-powered drug delivery patch for wound healing. The current generator provides excellent outputs of current and charge transfer which are advantageous for various biomedical applications.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
H02N 2/00 - Machines électriques en général utilisant l'effet piézo-électrique, l'électrostriction ou la magnétostriction
H02N 2/18 - Machines électriques en général utilisant l'effet piézo-électrique, l'électrostriction ou la magnétostriction fournissant une sortie électrique à partir d'une entrée mécanique, p. ex. générateurs
81.
ANALOG CONTENT ADDRESSABLE MEMORY CELL AND ARRAY FOR SOFT DECISION BOUNDARIES AND SOFT DECISION TREE COMPUTATION SYSTEM USING THE SAME
A SDT computation system is provided. The SDT computation system includes a SDT module, an ACAM array, and a mapping module. The SDT module is for outputting a final probability and configured to provide a SDT structure with a root node and deeper inner nodes for calculating probability, in which the final probability of each leaf node of the SDT structure is a product of all of node probabilities along a path from the root node to each leaf node, and wherein a final output of the SDT module is from a leaf with the highest probability. The mapping module is configured to map the SDT structure into the ACAM array, such that each of the ACAM cells in the ACAM array has a threshold programmed to be a parameter for a node in a path leading towards the leaf node of the SDT structure.
G11C 15/04 - Mémoires numériques dans lesquelles l'information, comportant une ou plusieurs parties caractéristiques, est écrite dans la mémoire et dans lesquelles l'information est lue au moyen de la recherche de l'une ou plusieurs de ces parties caractéristiques, c.-à-d. mémoires associatives ou mémoires adressables par leur contenu utilisant des éléments semi-conducteurs
G06N 7/02 - Agencements informatiques fondés sur des modèles mathématiques spécifiques utilisant la logique floue
G11C 27/00 - Mémoires analogiques électriques, p. ex. pour emmagasiner des valeurs instantanées
82.
I-DID SYSTEM FOR STRENGTHS-WEAKNESSES BASED ASSESSMENT AND INTERVENTION FOR DYSLEXIA
The I-DID system is strengths-weaknesses based assessment and intervention for dyslexia, particularly for dyslexia in bilingual users. The system includes a database comprising a large-scale profile of a plurality of user performance sets across five domains: language and literacy, cognition, creativity, music, and social-emotional skills. A machine learning-based subgroup generator creates subgroups to provide individualized intervention for each of the subgroups, such that the users in the different subgroups receive different interventions. The interventions comprise training in one or more domain-general cognitive and music skills, or language-specific listening, speaking, reading, writing, or combinations thereof. The combined theory-and data-driven approach of the system integrates multiple layers of online multifaceted assessments and classifies strength-weakness profiles of bilingual users for self-managed, personalized game-based intervention. The system promotes affordability, efficiency, equality and sustainability of clinical diagnosis and treatment for bilingual users along with users growing up in a multilingual environment.
GREM2 compositions and formulations thereof are described for use in treating or preventing one or more symptoms of a disease associated with loss of bone mineral density. Recombinant GREM2 have been shown to reduce bone resorption, reduce bone turnover markers, and increase bone strength. Methods of using the GREM2 compositions and formulations are also provided. Preferably, the pharmaceutical formulation containing GREM2 is administered via parenteral route to prevent or alleviate one or more symptoms of osteoporosis, osteopenia, bone fractures, and/or bone cancer.
C07K 14/51 - Facteur morphogénique osseuxOstéogénineFacteur ostéogéniqueFacteur inducteur d'os
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
C12N 15/12 - Gènes codant pour des protéines animales
84.
LOW-TEMPERATURE AGGLOMERATED HIGHLY-REFLECTED ELECTRODES FROM METALLIC NANOPARTICLES
The present invention provides a solution-processed metallic nanoparticle reflective electrode, which forms well-dispersed compactly packed structures during the stacking process. Featuring the self-packing ability of metallic nanoparticles and a higher space proportion, ligand-assisted metallic nanoparticles with a uniformdistribution of particle size and superior storage stability can formhigh-quality metallic nanoparticle filmin low-temperature sintering. Finally, attributing to the superior electrical and optical properties, and facile post-treatment of electrodes, a fully solution-processed OSCs with the ligand-assisted metallic nanoparticles electrodes achieve the record high efficiency of 14.69% for large-area devices (≥ 1 cm2).
Laboratory for Synthetic Chemistry and Chemical Biology Limited (Chine)
Inventeur(s)
Huang, Zhongxing
Zheng, Weifeng
Abrégé
Described herein are methods for preparing chiral α-amino acids using chiral phosphoric acids as catalysts. The disclosed methods can use amino-malonic acids as substrates to generate chiral amino acids with a variety of side chains in high optional purity (such as an ee value of at least 70%) and with a high yield (i.e., a yield of at least 80%, such as in a range from about 80% to about 99%), via an asymmetric decarboxylation reaction. The decarboxylation reaction of the methods is catalyzed by chiral phosphoric acids that can achieve a selective protonation during decarboxylation, which is considered one of the most difficult processes in asymmetric catalysis.
C07C 227/18 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C07C 229/42 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes carboxyle liés à des atomes de carbone acycliques du même squelette carboné avec des groupes carboxyle reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées saturées
C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
C07C 235/52 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
C07C 247/12 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone acycliques d'un squelette carboné étant substitué de plus par des groupes carboxyle
C07C 253/30 - Préparation de nitriles d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes cyano
C07C 255/30 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au même squelette carboné acyclique non saturé
C07C 255/58 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au squelette carboné
C07C 315/04 - Préparation de sulfonesPréparation de sulfoxydes par des réactions n'impliquant pas la formation de groupes sulfone ou sulfoxyde
C07C 317/48 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des groupes carboxyle liés au même squelette carboné le squelette carboné étant substitué de plus par des atomes d'azote liés par des liaisons simples, ne faisant pas partie de groupes nitro ou nitroso
C07D 207/16 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 209/24 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec un radical alkyle ou cycloalkyle lié à l'atome d'azote du cycle
C07D 209/48 - Iso-indolesIso-indoles hydrogénés avec des atomes d'oxygène en positions 1 et 3, p. ex. phtalimide
C07D 307/54 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 317/30 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 333/24 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 411/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène et de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
Dongguan Institute of Opto-electronics, Peking University (Chine)
Southern University of Science and Technology (Chine)
Inventeur(s)
Chu, Zhiqin
Jing, Jixiang
Wang, Qi
Wang, Zhongqiang
Li, Kwai Hei
Abrégé
The present invention provides a method for scalable fabrication of ultra-flat polycrystalline diamond membranes, the method comprising: (1) performing chemical vapor deposition on a growth substrate having diamond seeds thereon to grow a polycrystalline diamond membrane, wherein an exposed surface of the polycrystalline diamond membrane is a grown surface having a first roughness; and a surface bonded to the growth substrate is a buried surface; (2) bonding the grown surface to a transfer substrate using an adhesive; and (3) removing the growth substrate to expose the buried surface of the polycrystalline diamond membrane, wherein the buried surface has a second roughness after exposure, and the second roughness is less than the first roughness.
C30B 28/14 - Production de matériaux polycristallins homogènes de structure déterminée directement à partir de l'état gazeux par réaction chimique de gaz réactifs
C30B 29/64 - Cristaux plats, p. ex. plaques, bandes ou pastilles
C30B 33/12 - Gravure dans une atmosphère gazeuse ou un plasma
C30B 35/00 - Appareillages non prévus ailleurs, spécialement adaptés à la croissance, à la production ou au post-traitement de monocristaux ou de matériaux polycristallins homogènes de structure déterminée
87.
3D RECONSTITUTED BONE MARROW NICHE AND USES THEREOF
Advanced Biomedical Instrumentation Centre Limited (Chine)
Inventeur(s)
Chan, Pui Barbara
Cheung, Hoi Lam
Leung, Yu Hung Anskar
Kabigting, Jessica Evangeline Tan
Abrégé
Provided herein is a platform that supports the survival and phenotype maintenance of leukemia cells by co-culturing the cells with 3DON. The 3D osteogenic niche (3DON) mimics that in bone marrow to support AML cell survival in cultures before treatment with sample chemotherapy drug. The 3DON is comprised of osteogenically differentiated mesenchymal stromal cells (MSCs) microencapsulated in 3D microspheres made from extracellular matrix (ECM). Also provided is a method that increases the chemo-sensitivity of leukemia cells by co-culturing them with 3DON. The platform may be used for drug screening applications and the 3DON may be used as an adjuvant for chemotherapy.
A transcorneal electrical stimulation (TES) apparatus for treating brain diseases is provided. The apparatus includes an eye-contacting interface with at least one active electrode, an inactive reference electrode, and a current source. Both the active and reference electrodes are electrically connected to the current source, facilitating transcorneal electrical stimulation for various applications.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
Provided is a singlet oxygen-cleavable anti-VEGF prodrug. Provided is a composition comprising a photosensitizer and biocompatible polymer for the co-assembly of photoactivatable nanoparticles with the singlet oxygen-cleavable anti-VEGF prodrug. This red-light-activatable prodrug composition can be used in methods for the combined anti-angiogenesis and PDT treatment of wet AMD and other diseases, capable of light-controllable drug delivery to the CNV lesions and other disease sites via noninvasive intravenous administration.
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
Ocular antimicrobial compositions and methods and method of use thereof are provided. The compositions incorporate photoactive heterojunction materials can be incorporated into a suitable carrier, alone or in combination with an enzyme capable of generating ROS upon contact with the eye for the treatment of ocular conditions. The method includes contacting the eye of a subject in need thereof, the subject has or has been diagnosed with microbial keratitis, with an effective amount of the disclosed composition. The method further includes contacting the composition in the subject's eye with near infrared radiation (NIR).
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 41/17 - Inactivation ou décontamination d'une préparation médicinale avant son administration à un animal ou une personne par lumière ultraviolette [UV] ou infrarouge [IR], rayons X ou rayons gamma
A positioner comprising a nested pair of robots suitable for MRI-guided live-imaging, head-mounted bilateral stereotactic neurosurgery. Specifically, the positioner is suitable for locating a needle holder for tubular/needle-like instrument during neurosurgical operation. While maintaining a sufficient workspace (± 35°), the positioner remains lightweight (203 g) and compact ( Ø 81 mm × 97 mm height), enabling skull-mounted usage within most standard imaging head coils. The five-bar linkage architecture allows the reservation of exposure space around the incision port (burr hole on the skull) for operation/observation. The robot system operates in two stages: i) manual coarse adjustment within a large workspace performed interactively by the surgeon, followed by ii) automated fine adjustment within a localized motion range performed by soft fluid-driven actuators.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 17/06 - AiguillesSupports ou empaquetages pour aiguilles ou matériaux de suture
92.
NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (Chine)
Inventeur(s)
Huang, Yiran
Li, Xiaoyu
Abrégé
Provided herein are insulin receptor (INSR) agonists compounds of Formula I-IV or compositions containing the compounds, the use of these compounds or compositions in the treatment of diabetes. The compounds and compositions can bind to the allosteric sites on INSR and activate INSR and downstream signaling pathways synergistically with insulin by phosphorylating INSR proteins.
An event-guided auto-exposure (EG-AE) device leverages the high dynamic range and low latency properties of a dynamic vision sensor to guide the exposure setting of an active pixel sensor. The method utilizes physical connections of images and events to estimate the irradiance variations, which are fed into the EG-AE device for calculating the exposure setting. The method shows outstanding performance in tackling highly challenging lighting conditions and benefits multiple downstream applications, including visual tag detection and feature matching.
H04N 23/73 - Circuits de compensation de la variation de luminosité dans la scène en influençant le temps d'exposition
H04N 23/71 - Circuits d'évaluation de la variation de luminosité
H04N 23/72 - Combinaison de plusieurs commandes de compensation
H04N 23/74 - Circuits de compensation de la variation de luminosité dans la scène en influençant la luminosité de la scène à l'aide de moyens d'éclairage
H04N 25/47 - Capteurs d'images avec sortie d'adresse de pixelCapteurs d'images commandés par événementSélection des pixels à lire en fonction des données d'image
94.
ULTRASENSITIVE RAPID ANTIGEN DETECTION KIT AND DETECTION METHOD THEREOF
Advanced Biomedical Instrumentation Centre Limited (Hong Kong)
Inventeur(s)
Cao, Yang
Shum, Ho Cheung
Lin, Haisong
Abrégé
The present invention relates to an ultrasensitive rapid antigen detection kit for detecting N protein from SARS-CoV-2 virus in a sample, and methods for detecting N protein. The kit includes a sample collector, a collection and enrichment tube and a rapid antigen detection component with a test strip. The collection and enrichment tube contains a first part containing lyophilized ATPS reagents and a second part containing a lysis buffer. The sample is mixed with the lyophilized ATPS reagents and the lysis buffer to form a mixture. The enrichment is realized by concentrating the target analyte into one of the two phases formed by ATPS.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
95.
COMPOSITIONS AND METHODS FOR FAST MULTIPLEXED SCREENING AND MONITORING OF NPM1 MUTATIONS
Compositions and methods for the reliable molecular monitoring of NPM1 mutations are disclosed. The methods enable pre-emptive therapy essential for understanding AML disease status, informing therapeutic options, monitoring therapeutic efficacy, and improving patient outcome. The methods simultaneously screen and quantify samples having the major NPM1 mutant subtypes. In some forms, methods for detecting and measuring a presence, absence, and/or level of mutation of the NPM1 gene in a sample include hybridizing labelled sequence probes to the NPM1 gene in a sample to form labelled probe-nucleic acid conjugates, amplifying the probe-nucleic acid conjugates, and detecting the labelled probe-nucleic acid conjugates by measuring the level of one or more labels attached to the probes. The methods optionally record the presence, absence and/or level of NPM1 mutations in the sample.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
96.
METHOD AND APPARATUS FOR MICROPLASTIC IDENTIFICATION WITH POLARIZED DIGITAL HOLOGRAPHY
A method for aquatic microplastic identification is provided. The method includes steps as follows: emitting a laser beam from a laser source, such that the laser beam passes through a liquid sample with MP samples in a sample channel and then a polarizer and is received by polarization camera; capturing a sample image of the MP samples by the polarization camera, wherein the sample image comprises interference patterns resulting from superposition of object and reference waves; and feeding the interference patterns into a morphology analyzing module for real-time tracking and analyzing by using a lightweight convolutional neural network (CNN) model, so as to classify the MP samples.
G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
G03H 1/04 - Procédés ou appareils pour produire des hologrammes
G06V 10/147 - Détails de capteurs, p. ex. lentilles de capteurs
G06V 10/34 - Lissage ou élagage de la formeOpérations morphologiquesSquelettisation
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
The present invention provides a statistical acoustic sensing (SAS)-based method and system for in-vehicle Child Presence Detection. The SAS-based method comprises: transmitting acoustic signal to a subject in a vehicle cabin; receiving acoustic multipath signals scattered by the subject; and processing the acoustic multipath signals to detect presence of the subject by: extracting a plurality of channel impulse response (CIR) data from the received acoustic multipath signals; aggregating the extracted CIR data to estimate acoustic channel state information (CSI); obtaining an autocorrelation function (ACF) of the acoustic CSI based on a statistical acoustic sensing (SAS) model; and performing motion detection and breath tracking on basis of the ACF to detect presence of the subject in the vehicle cabin. The present invention can leverage in-car audio systems to detect presence of young children including newborns in an accurate and responsive manner.
Methods for detecting adaptive immune responses to pathogens or self-antigens by antibody or B cell or T cell binding to antigenic epitopes have been established. The methods inform functional and structural interactions between immune receptors and antigens, identify potential therapeutic targets and guide vaccine development. The methods employ high throughput modified mRNA-display or variations of droplet display to determine single epitope-specific antibody and B- and T- cell receptor sequences at the genomic scale at single epitope and single amino acid resolution. In some forms, the methods collect and integrate the data to provide a database of an adaptive immunity profile for a human or animal subject. In some forms, the methods identify and record changes in an immunity profile over different time points to reflect immunological responses in a subject. The methods provide high resolution immunity profiles of immune responses at the genomic level for diagnostic, prophylactic, and therapeutic applications.
A switchable triboelectric nanogenerator (s-TENG) which obtains energy by utilizing the electrostatic potential between water droplets and frictional surfaces. The s-TENG device includes an ITO film substrate as an electrode, a SU-8 mold grid located on the ITO film substrate and forming an array of air gaps as an air breakdown region, and a FEP film on the SU-8 mold grid as the surface of the friction layer. A water source is variably positioned at a distance from and at an angle to the s-TENG device so that water droplets contact the friction layer, so that direct current is obtained without the use of a rectifier due to electrostatic induction causing break down in the air breakdown region of the SU-8 mold grid.
The subject invention pertains to novel compounds, compositions containing the novel compounds, and methods for targeting gram-positive bacteria with the compounds or compositions of the subject invention. The subject invention further pertains to novel compounds, novel compositions, and methods for targeting gram-positive bacteria persister cells and gram-positive bacterial biofilms. The subject compounds and compositions can target gram-positive bacteria by modulating the proton motive force, calcium influx, autolysis, or any combination thereof. The novel compounds are synthetic, small molecules that can induce the death of gram-positive bacteria.
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
C07C 259/10 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p. ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes de carbone de cycles aromatiques à six chaînons
C07D 209/18 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 277/46 - Radicaux amino ou imino acylés par les acides carboxyliques ou par leurs analogues du soufre ou de l'azote
C07D 295/135 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
C07D 295/16 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle acylés sur les atomes d'azote du cycle
C07D 317/66 - Atomes d'azote ne faisant pas partie d'un radical nitro